Skip to main content
Premium Trial:

Request an Annual Quote

Immunexpress, Biocartis, Debiopharm to Further Develop Sepsis MDx

NEW YORK (GenomeWeb News) – Immunexpress Group, Biocartis, and Debiopharm Group today announced a collaboration to further develop Immunexpress' gene expression assay for managing sepsis.

Under the deal, Debiopharm will fund the validation and clearance from the US Food and Drug Administration of the test called SeptiCyte Triage. Biocartis will then fund the development and commercialization of the validated SeptiCyte assay on its fully integrated molecular diagnostics platform. The system includes an instrument, communication console, and single-use, disposable cartridges for detecting and quantifying multiple DNA or RNA biomarkers.

Debiopharm also is investing A$2 million (US$2 million) into Immunexpress.

SeptiCyte is a multiplex gene expression assay for use in emergency and intensive care units or upon hospital admission. It allows for the early diagnosis of sepsis, the differentiation of sepsis from other forms of inflammation, and the determination of sepsis severity, Immunexpress said.

"With accuracy significantly better than procalcitonin, bringing SeptiCyte Triage onto Biocartis' revolutionary point-of-need multiplex qRT-PCR platform will enable clinicians to more quickly and accurately identify and triage patients suspected of sepsis," Immunexpress President and CEO Roslyn Brandon said in a statement.

Financial and other terms of the deal were not disclosed.

Privately held Immunexpress develops molecular diagnostics for sepsis and has offices in Seattle and Brisbane, Australia.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.